Reformulated BeneFix®

Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

Thierry Lambert, Michael Recht, L. A. Valentino, J. S. Powell, C. Udata, S. T. Sullivan, D. A. Roth

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

BeneFix®, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent and allows for more concentrated infusions of recombinant FIX. A double-blind, randomized, pharmacokinetic (PK) crossover study demonstrated that reformulated BeneFix was bioequivalent to original B ene Fix and follow-up PK evaluation after 6 months of treatment demonstrated the PK stability of reformulated BeneFix after multiple exposures. Favourable efficacy and safety profiles, consistent with those already well-established for original BeneFix, were observed: 81.1% of haemorrhages resolved with only a single infusion; 85.3% of initial treatment response ratings were Excellent or Good; more than half of the subjects using reformulated BeneFix for routine prophylaxis (11 of 17, 64.7%) had no spontaneous haemorrhages during their 6-12 month course of prophylactic treatment, with an overall spontaneous bleeding rate of 0.72 year-1; and for the single surgical procedure (knee washing), treatment was rated Useful. In addition, there was no FIX inhibitor development, allergic-type manifestations, or thrombogenic complications with more than 1100 infusions (nearly 5.2 million IUs) administered in this trial. All efficacy and safety outcomes from this study were achieved with more concentrated recombinant protein infusions than that possible with original BeneFix, and utilization of the 2000 IU per vial dosage strength, newly introduced with the reformulated product, was high (>62%). The reformulation of BeneFix allows smaller delivery volumes and an increased choice of dosage strengths without altering the PK properties (including incremental recovery and half-life) or the established efficacy and safety profile of recombinant FIX.

Original languageEnglish (US)
Pages (from-to)233-243
Number of pages11
JournalHaemophilia
Volume13
Issue number3
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Hemophilia B
Factor IX
Pharmacokinetics
Safety
Hemorrhage
Therapeutics
Recombinant Proteins
Cross-Over Studies
Half-Life
Knee
Outcome Assessment (Health Care)

Keywords

  • BeneFix
  • Factor IX
  • Haemophilia B
  • Pharmacokinetics

ASJC Scopus subject areas

  • Hematology

Cite this

Reformulated BeneFix® : Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. / Lambert, Thierry; Recht, Michael; Valentino, L. A.; Powell, J. S.; Udata, C.; Sullivan, S. T.; Roth, D. A.

In: Haemophilia, Vol. 13, No. 3, 05.2007, p. 233-243.

Research output: Contribution to journalArticle

Lambert, Thierry ; Recht, Michael ; Valentino, L. A. ; Powell, J. S. ; Udata, C. ; Sullivan, S. T. ; Roth, D. A. / Reformulated BeneFix® : Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. In: Haemophilia. 2007 ; Vol. 13, No. 3. pp. 233-243.
@article{4b1fd0751fe14ffda5bea165486cfbd9,
title = "Reformulated BeneFix{\circledR}: Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B",
abstract = "BeneFix{\circledR}, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent and allows for more concentrated infusions of recombinant FIX. A double-blind, randomized, pharmacokinetic (PK) crossover study demonstrated that reformulated BeneFix was bioequivalent to original B ene Fix and follow-up PK evaluation after 6 months of treatment demonstrated the PK stability of reformulated BeneFix after multiple exposures. Favourable efficacy and safety profiles, consistent with those already well-established for original BeneFix, were observed: 81.1{\%} of haemorrhages resolved with only a single infusion; 85.3{\%} of initial treatment response ratings were Excellent or Good; more than half of the subjects using reformulated BeneFix for routine prophylaxis (11 of 17, 64.7{\%}) had no spontaneous haemorrhages during their 6-12 month course of prophylactic treatment, with an overall spontaneous bleeding rate of 0.72 year-1; and for the single surgical procedure (knee washing), treatment was rated Useful. In addition, there was no FIX inhibitor development, allergic-type manifestations, or thrombogenic complications with more than 1100 infusions (nearly 5.2 million IUs) administered in this trial. All efficacy and safety outcomes from this study were achieved with more concentrated recombinant protein infusions than that possible with original BeneFix, and utilization of the 2000 IU per vial dosage strength, newly introduced with the reformulated product, was high (>62{\%}). The reformulation of BeneFix allows smaller delivery volumes and an increased choice of dosage strengths without altering the PK properties (including incremental recovery and half-life) or the established efficacy and safety profile of recombinant FIX.",
keywords = "BeneFix, Factor IX, Haemophilia B, Pharmacokinetics",
author = "Thierry Lambert and Michael Recht and Valentino, {L. A.} and Powell, {J. S.} and C. Udata and Sullivan, {S. T.} and Roth, {D. A.}",
year = "2007",
month = "5",
doi = "10.1111/j.1365-2516.2007.01458.x",
language = "English (US)",
volume = "13",
pages = "233--243",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Reformulated BeneFix®

T2 - Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

AU - Lambert, Thierry

AU - Recht, Michael

AU - Valentino, L. A.

AU - Powell, J. S.

AU - Udata, C.

AU - Sullivan, S. T.

AU - Roth, D. A.

PY - 2007/5

Y1 - 2007/5

N2 - BeneFix®, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent and allows for more concentrated infusions of recombinant FIX. A double-blind, randomized, pharmacokinetic (PK) crossover study demonstrated that reformulated BeneFix was bioequivalent to original B ene Fix and follow-up PK evaluation after 6 months of treatment demonstrated the PK stability of reformulated BeneFix after multiple exposures. Favourable efficacy and safety profiles, consistent with those already well-established for original BeneFix, were observed: 81.1% of haemorrhages resolved with only a single infusion; 85.3% of initial treatment response ratings were Excellent or Good; more than half of the subjects using reformulated BeneFix for routine prophylaxis (11 of 17, 64.7%) had no spontaneous haemorrhages during their 6-12 month course of prophylactic treatment, with an overall spontaneous bleeding rate of 0.72 year-1; and for the single surgical procedure (knee washing), treatment was rated Useful. In addition, there was no FIX inhibitor development, allergic-type manifestations, or thrombogenic complications with more than 1100 infusions (nearly 5.2 million IUs) administered in this trial. All efficacy and safety outcomes from this study were achieved with more concentrated recombinant protein infusions than that possible with original BeneFix, and utilization of the 2000 IU per vial dosage strength, newly introduced with the reformulated product, was high (>62%). The reformulation of BeneFix allows smaller delivery volumes and an increased choice of dosage strengths without altering the PK properties (including incremental recovery and half-life) or the established efficacy and safety profile of recombinant FIX.

AB - BeneFix®, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent and allows for more concentrated infusions of recombinant FIX. A double-blind, randomized, pharmacokinetic (PK) crossover study demonstrated that reformulated BeneFix was bioequivalent to original B ene Fix and follow-up PK evaluation after 6 months of treatment demonstrated the PK stability of reformulated BeneFix after multiple exposures. Favourable efficacy and safety profiles, consistent with those already well-established for original BeneFix, were observed: 81.1% of haemorrhages resolved with only a single infusion; 85.3% of initial treatment response ratings were Excellent or Good; more than half of the subjects using reformulated BeneFix for routine prophylaxis (11 of 17, 64.7%) had no spontaneous haemorrhages during their 6-12 month course of prophylactic treatment, with an overall spontaneous bleeding rate of 0.72 year-1; and for the single surgical procedure (knee washing), treatment was rated Useful. In addition, there was no FIX inhibitor development, allergic-type manifestations, or thrombogenic complications with more than 1100 infusions (nearly 5.2 million IUs) administered in this trial. All efficacy and safety outcomes from this study were achieved with more concentrated recombinant protein infusions than that possible with original BeneFix, and utilization of the 2000 IU per vial dosage strength, newly introduced with the reformulated product, was high (>62%). The reformulation of BeneFix allows smaller delivery volumes and an increased choice of dosage strengths without altering the PK properties (including incremental recovery and half-life) or the established efficacy and safety profile of recombinant FIX.

KW - BeneFix

KW - Factor IX

KW - Haemophilia B

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=34248532042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248532042&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2007.01458.x

DO - 10.1111/j.1365-2516.2007.01458.x

M3 - Article

VL - 13

SP - 233

EP - 243

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 3

ER -